Swanson said Roche’s phase 3 decision was informed by results from two phase 2 trials, PADOVA and PASADENA , and open-label extension data. He highlighted an exploratory endpoint from PADOVA presented by Roche at ADPD 2025: in a subset of participants (about 75% of the PADOVA population) who were on stable levodopa, prasinezumab showed a 40% relative reduction in progression on MDS-UPDRS part 3 versus placebo at 24 months, with a nominal p-value of 0.0177 . He said aspects of the phase 3 design were optimiz ...